Janux Therapeutics
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $7,880 | $10,000 | $0 | $0 |
Gross Profit | -1,060 | 9,499 | -541 | -519 |
EBITDA | -75,469 | -23,812 | -44,577 | -34,378 |
EBIT | -75,988 | -24,313 | -45,118 | -34,897 |
Net Income | -75,988 | -24,313 | -33,858 | -23,508 |
Net Change In Cash | 7,880 | 10,000 | 0 | 0 |
Free Cash Flow | 54,630 | -12,949 | -24,286 | -17,395 |
Cash | 52,334 | 48,389 | 52,446 | 73,743 |
Basic Shares | 61,966 | 62,023 | 61,902 | 61,791 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $10,000 | $10,588 | $8,083 | $8,612 |
Gross Profit | 8,528 | 6,128 | 8,612 | |
EBITDA | -113,625 | -96,787 | -71,024 | -66,250 |
EBIT | -98,847 | -72,979 | -67,091 | |
Net Income | -157,667 | -68,994 | -58,293 | -54,154 |
Net Change In Cash | 10,000 | 10,588 | 8,083 | 8,612 |
Cost of Revenue | 15,844 | |||
Free Cash Flow | -44,173 | -52,425 | -49,367 | |
Cash | 52,334 | 430,605 | 19,205 | 51,426 |
Basic Shares | 61,966 | 53,751 | 44,016 | 41,469 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-12-31 | -$0.51 |
2025-09-30 | -$0.39 |
2025-06-30 | -$0.55 |
2025-03-31 | -$0.38 |
